160 related articles for article (PubMed ID: 22106282)
1. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.
Lee JH; Choy ML; Ngo L; Venta-Perez G; Marks PA
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19629-34. PubMed ID: 22106282
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
Brazelle W; Kreahling JM; Gemmer J; Ma Y; Cress WD; Haura E; Altiok S
PLoS One; 2010 Dec; 5(12):e14335. PubMed ID: 21179472
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe.
Cornago M; Garcia-Alberich C; Blasco-Angulo N; Vall-Llaura N; Nager M; Herreros J; Comella JX; Sanchis D; Llovera M
Cell Death Dis; 2014 Oct; 5(10):e1435. PubMed ID: 25275596
[TBL] [Abstract][Full Text] [Related]
5. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.
Dai Y; Chen S; Kmieciak M; Zhou L; Lin H; Pei XY; Grant S
Mol Cancer Ther; 2013 Jun; 12(6):878-89. PubMed ID: 23536721
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Mitchell C; Park M; Eulitt P; Yang C; Yacoub A; Dent P
Mol Pharmacol; 2010 Nov; 78(5):909-17. PubMed ID: 20696794
[TBL] [Abstract][Full Text] [Related]
8. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
9. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Parsels LA; Qian Y; Tanska DM; Gross M; Zhao L; Hassan MC; Arumugarajah S; Parsels JD; Hylander-Gans L; Simeone DM; Morosini D; Brown JL; Zabludoff SD; Maybaum J; Lawrence TS; Morgan MA
Clin Cancer Res; 2011 Jun; 17(11):3706-15. PubMed ID: 21482692
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
Namdar M; Perez G; Ngo L; Marks PA
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity.
Smith S; Fox J; Mejia M; Ruangpradit W; Saberi A; Kim S; Choi Y; Oh S; Wang Y; Choi K; Li L; Hendrickson EA; Takeda S; Muller M; Myung K
PLoS One; 2014; 9(1):e87203. PubMed ID: 24466340
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
[TBL] [Abstract][Full Text] [Related]
13. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
14. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S
Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
17. p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 Arrest.
Wang XQ; Stanbridge EJ; Lao X; Cai Q; Fan ST; Redpath JL
Radiat Res; 2007 Dec; 168(6):706-15. PubMed ID: 18088187
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells.
Petruccelli LA; Dupéré-Richer D; Pettersson F; Retrouvey H; Skoulikas S; Miller WH
PLoS One; 2011; 6(6):e20987. PubMed ID: 21695163
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.
Syljuåsen RG; Sørensen CS; Hansen LT; Fugger K; Lundin C; Johansson F; Helleday T; Sehested M; Lukas J; Bartek J
Mol Cell Biol; 2005 May; 25(9):3553-62. PubMed ID: 15831461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
